RLYB Market Analysis

News & Sentiment

50 articles · sorted by date
Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Fundamentals

Updated daily after market close
P/E ratio
EPS (TTM)$-1.360.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$84.5MMicro cap

Valuation

Forward P/E
PEG ratio
P/B
1.68
P/S (TTM)
98.53
EV/EBITDA
-1.41

Profitability & growth

ROE (TTM)
-15.0%
Operating margin
-3787.0%
Revenue growth YoY
0.0%
Dividend yield
Beta
-0.89
Last earnings
May 13, 2026 · Estimate $-1.20 · Reported $-1.46
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About Rallybio Corp

Company profile

Rallybio Corp is a clinical-stage biotechnology company focused on developing innovative therapies for rare diseases, especially within immunology and hematology. The company boasts a promising pipeline of biologic drug candidates that are currently advancing through clinical trials, backed by an experienced management team with significant industry expertise. By forming strategic partnerships, Rallybio enhances its capacity to deliver transformative treatments in underserved therapeutic areas, demonstrating its commitment to improving patient outcomes. With a well-defined strategy and a…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
234 CHURCH STREET, NEW HAVEN, CT
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$84.5M
Shares outstanding$5.3M
52W high$17.57
52W low$3.20

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer